About Us

QT Imaging Breast Center Dr Susan Love Foundation logo

Dr. Susan Love Foundation for Breast Cancer Research challenges the status quo to end breast cancer and improve the lives of people impacted by it through education and advocacy. The Foundation drives collaborative, cutting-edge research with nontraditional partners, brings to light the collateral damage of treatment and seeks ways to diminish it, and interprets science to empower patients. Fast, flexible, and project-based, the Foundation actively engages the public in scientific research to ensure that it produces accurate and meaningful results. Foundation CEO Christopher Clinton Conway says,

“The Foundation’s work advancing Dr. Susan Love’s research into the breast ducts intersects seamlessly with Dr. John Klock’s innovative technology in the QTscan®. The interaction of brilliant minds with technology will allow us to better diagnose and prevent breast cancer. This is truly the next chapter of innovation and research for which the Foundation is best recognized. Mostly we’re excited for what that means for breast cancer prevention.”


QT Imaging®, led by CEO Dr. John Klock, is a privately held tech company advancing the research, development, and commercialization of an innovative automated breast imaging system producing high-resolution transmission ultrasound images. Dr. Klock has previously brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating genetic conditions in pediatric patients. Says Dr. Klock,

“Innovation is nothing new for QT Imaging®, and partnering with the Foundation in this next phase is simply another way to advance treatment in breast cancer care.”

Over the past four years, we have studied a collection of QT Ultrasound images to identify both the usual patterns of ducts inside the breast and the changes the breast tissue undergoes throughout the menstrual cycle in women. The QTscan® used in this study has now received FDA clearance to measure fibro glandular volume. This next phase of this project with QT Imaging® will allow for the detection of cancerous lesions that a mammogram may have missed in a previous recent negative mammogram in women with dense breasts. It is estimated that 47% of women have dense breasts, which can make it more difficult to identify breast cancer on a mammogram making women with dense breast tissue at higher risk of a breast cancer diagnosis.